Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2734]

Scientists design a new tumour-targeting system for cancer fighting cells

Scientists design a new tumour-targeting system for cancer fighting cells

Exercise during chemotherapy may help immune cells fight cancer – patients invited to join new trial

Exercise during chemotherapy may help immune cells fight cancer – patients invited to join new trial

ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study...

ASCO 2025: Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers

ASCO 2025: Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast...

ASCO 2025: Ramucirumab and pembrolizumab combo does not improve OS for previously treated advanced NSCLC

ASCO 2025: Ramucirumab and pembrolizumab combo does not improve OS for previously treated advanced NSCLC

ASCO 2025: Nivolumab plus chemo before surgery improves lung cancer survival

ASCO 2025: Nivolumab plus chemo before surgery improves lung cancer survival

ASCO 2025: Adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in head and neck cancer

ASCO 2025: Adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in head and neck...

ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer

ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer

ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric...

ASCO 2025: Molecular assay may help identify people with NSCLC who could benefit from adjuvant chemotherapy

ASCO 2025: Molecular assay may help identify people with NSCLC who could benefit from adjuvant chemotherapy

More from ecancer